Scilex Holding Co (FRA:D8B0) 1-Year Sharpe Ratio: N/A (As of Sep. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:D8B0 Scilex Holding Co FRA:D8B0
41 GF Score
Price €4.28
GF Value €5.35
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Scilex Holding Co 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-07), Scilex Holding Co's 1-Year Sharpe Ratio is Not available.

Scilex Holding Co  (FRA:D8B0) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Scilex Holding Co 1-Year Sharpe Ratio Related Terms

FRA:D8B0 vs MIRA, NSRX, MDCX: 1-Year Sharpe Ratio Comparison

For the Drug Manufacturers - General subindustry, Scilex Holding Co's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scilex Holding Co 1-Year Sharpe Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Scilex Holding Co's 1-Year Sharpe Ratio falls into.


FRA:D8B0
41GF Score
Scilex Holding Co FRA:D8B0
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scilex Holding Co 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Is Scilex Holding Co (FRA:D8B0) Overvalued in 2026?

Based on GuruFocus' analysis, Scilex Holding Co stock appears to be undervalued. The current stock price of €4.28 is trading 20% below its estimated GF Value™ of €5.35. GuruFocus considers Scilex Holding Co to be Modestly Undervalued.

Key valuation signals for FRA:D8B0:

  • 1-Year Sharpe Ratio: N/A
  • GF Value™: €5.35 vs. price of €4.28 (20% below fair value)
  • GF Score™: 41/100 with 7 warning signs

No single metric tells the full story. See the FRA:D8B0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scilex Holding Co Business Description

Other Exchanges SCLX:USA
Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
41GF Score

Get the complete analysis for FRA:D8B0

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.28
Price
€5.35
GF Value